Abstract:Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel diseases (IBD), are chronic, relapsing inflammatory disorders of the gastrointestinal (GI) tract. IBD affects over 1 million individuals in the United States and approximately 2.5 million in Europe [1; 2]. Although IBD is a global health concern with the highest prevalence in Western countries, newly industrialized regions in Asia, the Middle East, Africa, and South America have seen a rapid rise in the disease incidence [2]. Despite extensive research, the precise etiology and pathogenesis of IBD remain unclear. However, genome-wide association studies have identified more than 200 IBD-associated susceptibility genes, several of which are involved in mediating host responses to the gut microbiota [3; 4]. This finding has led to increasing interest in the role of the gut microbiota in IBD pathogenesis.The human gut is the home to approximately 100 trillion microorganisms, including bacteria, viruses, fungi, and protozoa, collectively referred to as the gut microbiota. Using culture-independent molecular methods, it is estimated that over 1,000 species of bacteria inhabit the GI tract, and the combined genome of these intestinal microbes contains roughly 100 times more genes than the human genome [5]. More than 99% of intestinal bacteria fall within four major phyla: Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria. Of these, the two dominant phyla in healthy adults are Firmicutes and Bacteroidetes [6].The abundance and composition of bacteria vary significantly across different regions of the GI tract. The stomach and upper small intestine host relatively few microbial species, while the number of bacteria increases progressively from the jejunum to the colon [4].Li et al. employed a Mendelian randomization approach to explore the causal relationships between gut microbiota composition and subtypes of CD and UC. The researchers identified specific bacterial taxa, such as Hungatella and Acidaminococcaceae, as protective factors against certain subtypes of IBD, while others like Terrisporobacter and Anaerostipes were associated with increased risk. These findings suggested that dysbiosis may vary between IBD subtypes, with implications for personalized therapeutic interventions targeting specific microbial communities depending on the IBD subtype [3].Expanding on this, Kulecka et al. examined the interaction between gut microbiota and Clostridioides difficile infection (CDI) in patients with IBD and cancer-related diarrhea. The researchers found that IBD and cancer patients both exhibited gut dysbiosis characterized by reduced microbial diversity. CDI further exacerbated this dysbiosis, leading to a significant reduction in beneficial bacteria such as Bacteroides fragilis, while increasing the abundance of pathogenic species like Escherichia coli and Klebsiella pneumoniae. The reduction in short-chain fatty acid (SCFA)-producing bacteria (such as those generating butyrate and propionate) was linked to worsened gut inflammation and disruption of intestinal homeostasis [7].Further exploring systemic connections, Du et al. investigated the concept of lung-gut crosstalk, highlighting the mutual influence between respiratory diseases and IBD. The authors suggested that both lungs and intestines are integral parts of the common mucosal immune system, with immune responses in one organ affecting the other. The review emphasized that gut microbial imbalances could contribute to respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), while respiratory diseases could exacerbate IBD symptoms. The presence of dysbiosis in both conditions suggests potential for shared therapeutic strategies targeting gut microbiota to improve outcomes in both lung and intestinal diseases [8; 9]. In a different vein, Hou et al. focused on the role of the aryl hydrocarbon receptor (AHR) in the context of IBD, with particular attention to how gut microbiota influences AHR activation. The authors discussed how microbial metabolites, such as tryptophan derivatives, can activate AHR, which in turn plays a crucial role in regulating immune responses, inflammation, and maintaining gut barrier integrity. In IBD, a decrease in AHR activity was associated with more severe inflammation and dysbiosis, indicating that therapeutic strategies aimed at enhancing AHR activation could alleviate IBD symptoms. The review also highlighted the potential for non-toxic natural AHR ligands to present as new therapeutic agents.In conclusion, the published studies in this Research Topic highlight the significant importance of gut microbiota in the pathogenesis and management of IBD and irritable bowel syndrome (IBS). Dysbiosis, or the disruption of microbial balance, is a common feature in both IBD and IBS, contributing to inflammation and disease progression [3]. Collectively, these s -Abstract Truncated-

Mesenteric Organ Lymphatics and Inflammatory Bowel Disease.

Implications of lymphatic alterations in the pathogenesis and treatment of inflammatory bowel disease

Relationship Between Mesentery and Crohn's Disease

Cellular and molecular mediators of lymphangiogenesis in inflammatory bowel disease

The Role of the Lymphatic System in the Pathogenesis and Treatment of Inflammatory Bowel Disease

Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics

Molecular Mechanisms of Hepatobiliary and Pancreatic Diseases in Patients with Inflammatory Bowel Disease

Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease

Interplay of Intestinal Microbiota and Mucosal Immunity in Inflammatory Bowel Disease: a Relationship of Frenemies

Acute small intestinal inflammation results in persistent lymphatic alterations

New Insights into Bacterial Mechanisms and Potential Intestinal Epithelial Cell Therapeutic Targets of Inflammatory Bowel Disease

Effect of Dysbiosis of Intestinal Microbiota in Inflammatory Bowel Disease

Dissecting Innate and Adaptive Immunity in Inflammatory Bowel Disease: Immune Compartmentalization, Microbiota Crosstalk, and Emerging Therapies

Current Insights on the Roles of Gut Microbiota in Inflammatory Bowel Disease-Associated Extra-Intestinal Manifestations: Pathophysiology and Therapeutic Targets

Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease

Toll-Like Receptors And Inflammatory Bowel Disease

Editorial: Recent advances in understanding the role and mechanisms of gut microbiota in inflammatory bowel disease and irritable bowel syndrome

Association between intestinal microbiota and inflammatory bowel disease

Intestinal Inflammation and Regeneration–Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease

The Role of Tissue-Resident Macrophages in the Development and Treatment of Inflammatory Bowel Disease

Involvement of Embryo-Derived and Monocyte-Derived Intestinal Macrophages in the Pathogenesis of Inflammatory Bowel Disease and Their Prospects as Therapeutic Targets